Johnson & Johnson (J&J), on Friday, August 6, confirmed that it is seeking emergency authorization in the Indian market for its single-dose vaccines against the CCP virus (COVID-19).
If approved, the one-shot vaccines would be available to India and many others worldwide via Biological E Limited, an Indian pharmaceutical firm.
“Biological E will be an important part of our global supply chain network, helping to supply our Johnson & Johnson COVID-19 vaccine through the extensive collaborations and partnerships we have with governments, health authorities, and organizations such as Gavi and the COVAX Facility,” said a Johnson & Johnson India spokesperson in a statement, according to Rediff.
“We look forward to concluding our discussions with the government of India to accelerate the availability of our COVID-19 vaccine to help end the pandemic,” the statement continued.
According to the outlet, the company applied for the emergency approval based on its Phase 3 ENSEMBLE clinical trial, which showed that the one-shot vaccine was 85% capable of preventing severe illnesses caused by the CCP virus, as well as effective in hindering COVID-19 related hospitalization and death 28 days after vaccination.
India has authorized the vaccines made by AstraZeneca, Bharat Biotech, Russia’s Gamaleya Institute, and Moderna. Biological E is also in the process of developing the COVID-19 vaccine version, called the Corbevax, according to Hindustan Times.
The government and Moderna are still working out challenges with vaccine importation and indemnity, Reuters noted.
India became COVID-19 epicenter around April and May this year, as the country was savaged by the CCP virus much worse than its first outburst in 2020.
It hit the worst moment when nearly 5,000 new deaths were officially recorded each day, with experts anticipating many others had gone unreported. A study alleged the real death toll might have exceeded 4 million patients by mid-July, per the BBC.
Throughout the past week, the country had witnessed more than 40,000 cases each day, with daily deaths standing between 500 and 600 cases, according to data by Worldometers.
As of Friday, just 495.3 million people out of a population of over 1.3 billion had received at least one dosage of the vaccine, data from the Indian health ministry.
Last month, the Food and Drug Administration (FDA) warned that the J&J doses could lead to a rare neurological disorder.